Gimistotug

N/A

Report date: 2025/05/20 15:34:32

Base Information

Drug NameGimistotug
Drug Alias NameBGB-A445
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonists
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNasopharyngeal Carcinoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeigene Guangzhou Biologics Manufacturing Co LtdBeOne Medicines LtdBeigene (Shanghai) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNasopharyngeal Carcinoma +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A